糖尿病中的高胰高血糖素血症:氨基酸代谢改变触发mTORC1激活,进而驱动胰高血糖素分泌
该研究探讨营养素如何经mTORC1调控胰岛α细胞功能。在糖尿病Akita小鼠中α细胞mTORC1活性随高血糖和高胰高血糖素血症而升高;氨基酸刺激α细胞mTORC1,高糖则抑制之,但长期高糖使该抑制消失、mTORC1持续激活并增加胰高血糖素分泌。α细胞特异性Rptor敲除可抑制mTORC1、减少胰高血糖素分泌并改善糖尿病。
要点
- 糖尿病Akita小鼠α细胞mTORC1活性随高血糖和高胰高血糖素血症升高2至8倍
- 氨基酸急性刺激小鼠和人胰岛α细胞mTORC1升高3.5倍,高糖抑制mTORC1降低1.4倍
- 成年糖尿病小鼠α细胞Rptor敲除使胰高血糖素分泌减少约6倍并改善糖尿病
核心结论
- α细胞暴露于高血糖可增强氨基酸合成与转运,导致mTORC1持续激活,从而增加胰高血糖素分泌。
- mTORC1在介导糖尿病α细胞功能障碍中起主要作用。
研究设计与样本
- 研究采用糖尿病Akita小鼠模型、人及小鼠胰岛和α细胞系αTC1-6,评估α细胞mTORC1活性。
- 通过免疫染色检测核糖体蛋白S6磷酸化和胰高血糖素,并进行共聚焦显微镜和流式细胞术分析。
- 采用13C葡萄糖标记在2.8或16.7 mmol/l葡萄糖条件下进行代谢组学和代谢流分析,并用LC-MS检测。
- 在成年糖尿病Akita小鼠中构建可诱导的α细胞特异性Rptor敲除,通过IPGTT和胰高血糖素分泌评估效果。
主要发现
- 糖尿病Akita小鼠α细胞mTORC1活性随高血糖和高胰高血糖素血症发展而升高,增幅为2至8倍。
- 小鼠和人胰岛急性暴露于氨基酸使α细胞mTORC1升高3.5倍,而高糖浓度抑制mTORC1降低1.4倍。
- 人和小鼠糖尿病α细胞在长期高糖暴露后对葡萄糖的mTORC1反应消失,导致mTORC1持续激活并伴胰高血糖素分泌增加。
- 高糖暴露增强糖酵解、葡萄糖氧化和葡萄糖来源氨基酸合成,并增加Slc7a2和Slc38a4表达及支链氨基酸和甲硫氨酸循环代谢物水平(两者均约升高1.3倍)。
- 成年糖尿病小鼠α细胞条件性Rptor敲除抑制mTORC1,使胰高血糖素分泌减少约6倍并改善糖尿病,尽管胰岛素缺乏持续存在。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM/HYPOTHESIS: Hyperglycaemia is associated with alpha cell dysfunction, leading to dysregulated glucagon secretion in type 1 and type 2 diabetes; however, the mechanisms involved are still elusive. The nutrient sensor mammalian target of rapamycin complex 1 (mTORC1) plays a major role in the maintenance of alpha cell mass and function. We studied the regulation of alpha cell mTORC1 by nutrients and its role in the development of hyperglucagonaemia in diabetes. METHODS: Alpha cell mTORC1 activity was assessed by immunostaining for phosphorylation of its downstream target, the ribosomal protein S6, and glucagon, followed by confocal microscopy on pancreatic sections and flow cytometry on dispersed human and mouse islets and the alpha cell line, αTC1-6. Metabolomics and metabolic flux were studied by 13C glucose labelling in 2.8 or 16.7 mmol/l glucose followed by LC-MS analysis. To study the role of mTORC1 in mediating hyperglucagonaemia in diabetes, we generated an inducible alpha cell-specific Rptor knockout in the Akita mouse model of diabetes and tested the effects on glucose tolerance by IPGTT and on glucagon secretion. RESULTS: mTORC1 activity was increased in alpha cells from diabetic Akita mice in parallel to the development of hyperglycaemia and hyperglucagonaemia (two- to eightfold increase). Acute exposure of mouse and human islets to amino acids stimulated alpha cell mTORC1 (3.5-fold increase), whereas high glucose concentrations inhibited mTORC1 (1.4-fold decrease). The mTORC1 response to glucose was abolished in human and mouse diabetic alpha cells following prolonged islet exposure to high glucose levels, resulting in sustained activation of mTORC1, along with increased glucagon secretion. Metabolomics and metabolic flux analysis showed that exposure to high glucose levels enhanced glycolysis, glucose oxidation and the synthesis of glucose-derived amino acids. In addition, chronic exposure to high glucose levels increased the expression of Slc7a2 and Slc38a4, which encode amino acid transporters, as well as the levels of branched-chain amino acids and methionine cycle metabolites (~1.3-fold increase for both). Finally, conditional Rptor knockout in alpha cells from adult diabetic mice inhibited mTORC1, thereby inhibiting glucagon secretion (~sixfold decrease) and improving diabetes, despite persistent insulin deficiency. CONCLUSIONS/INTERPRETATION: Alpha cell exposure to hyperglycaemia enhances amino acid synthesis and transport, resulting in sustained activation of mTORC1, thereby increasing glucagon secretion. mTORC1 therefore plays a major role in mediating alpha cell dysfunction in diabetes. DATA AVAILABILITY: All sequencing data are available from the Gene Expression Omnibus (GEO) repository (accession no. GSE154126; https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE154126 ).
引用
- Riahi Y, Kogot-Levin A, Kadosh L, et al. Hyperglucagonaemia in diabetes: altered amino acid metabolism triggers mTORC1 activation, which drives glucagon production. Diabetologia. 2023. PMID: 37480416. doi:10.1007/s00125-023-05967-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。